ALKERMES | ALKS - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Malin Corporation EUR 198.5M 70.1M 2024-12
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Otsuka Holdings JPY 4.21T 11.63B 2026-03
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03